Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 13/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.49 |
| ▸ | PPARD | Q03181 | 13/20 | 0.42 |
| ▸ | PPARA | Q07869 | 13/20 | 0.42 |
| ▸ | PPARG | P37231 | 10/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5576769 | 0.86 | NR1H2 (0.56) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6099203 | 0.85 | NR1H3 (0.67) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6407458 | 0.84 | NR1H2 (0.41) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6102250 | 0.84 | NR1H3 (0.66) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6422304 | 0.83 | GRM2 (0.58) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6098942 | 0.81 | GRM2 (0.55) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6097922 | 0.81 | NR1H2 (0.74) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6406097 | 0.78 | NR1H2 (0.47) | NR1H2NR1H3PPARDPPARAPPARG | |
| SCHEMBL6100087 | 0.78 | GRM2 (0.63) | GRM2NR1H2NR1H3PPARDPPARA | |
| SCHEMBL6175566 | 0.77 | GRM2 (0.60) | GRM2NR1H2NR1H3PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | claimed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | claimed |
| US-7125865-B2 | Therapeutic compounds for treating dyslipidemic conditions | MERCK & CO., INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | MERCK SHARP & DOHME CORP. | 2005-10-27 | — | — | US | disclosed |
| EP-1534696-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004011448-A1 | THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS | MERCK & CO., INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239769-A1 | Therapeutic compounds for treating dyslipidemic conditions | NR1H2, NR1H3, LDLR | GRM2 541/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.